Antiproliferative effects of somatostatin analogs in pituitary adenomas.
The antisecretory effects of somatostatin (SRIF) and its analogs are widely recognised and provide the basis for treatment of hormonal hypersecretion in pituitary adenomas, especially in the settings of acromegaly. Evidence for an antiproliferative effect of these compounds has also been provided. This review focuses on the mechanisms transducing the antiproliferative effects of SRIF and its analogs on pituitary adenomas, and on the clinical consequences on tumor volume of pharmacological treatment of pituitary adenomas with these drugs.
Zatelli
Maria Chiara
MC
Section of Endocrinology, Department of Biomedical Sciences and Advanced Therapies, University of Ferrara, 44100, Ferrara, Italy.
Piccin
Daniela
D
Ambrosio
Maria Rosaria
MR
Bondanelli
Marta
M
degli Uberti
Ettore C
EC
D000236:Adenoma / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D000595:Amino Acid Sequence; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002455:Cell Division / Q000187:drug effects; D006801:Humans; D008969:Molecular Sequence Data; D010911:Pituitary Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D011487:Protein Conformation; D016032:Randomized Controlled Trials as Topic; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000737:chemistry / Q000378:metabolism / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D013004:Somatostatin